Lambert et al., 2021 - Google Patents
HIV-1 envelope glycosylation and the signal peptideLambert et al., 2021
View HTML- Document ID
- 7036485011984261545
- Author
- Lambert G
- Upadhyay C
- Publication year
- Publication venue
- Vaccines
External Links
Snippet
The RV144 trial represents the only vaccine trial to demonstrate any protective effect against HIV-1 infection. While the reason (s) for this protection are still being evaluated, it serves as justification for widespread efforts aimed at developing new, more effective HIV-1 vaccines …
- 241000713772 Human immunodeficiency virus 1 0 title abstract description 178
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse Transcribing RNA Viruses
- C12N2740/00011—Reverse Transcribing RNA Viruses
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
- C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses, e.g. hepatitis E virus
- C07K16/1036—Retroviridae, e.g. leukemia viruses
- C07K16/1045—Lentiviridae, e.g. HIV, FIV, SIV
- C07K16/1063—Lentiviridae, e.g. HIV, FIV, SIV env, e.g. gp41, gp110/120, gp160, V3, PND, CD4 binding site
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Xiao et al. | HIV-1 entry and membrane fusion inhibitors | |
| Mu et al. | HIV mRNA vaccines—progress and future paths | |
| Gao et al. | Advances in HIV-1 vaccine development | |
| Trovato et al. | HIV vaccination: a roadmap among advancements and concerns | |
| Morales-Núñez et al. | Overview of neutralizing antibodies and their potential in COVID-19 | |
| Lewis et al. | Conformational masking and receptor-dependent unmasking of highly conserved Env epitopes recognized by non-neutralizing antibodies that mediate potent ADCC against HIV-1 | |
| Kwong et al. | HIV-1 and influenza antibodies: seeing antigens in new ways | |
| Caillat et al. | Neutralizing antibodies targeting HIV-1 gp41 | |
| Liu et al. | Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer | |
| Pu et al. | Development of protein-and peptide-based HIV entry inhibitors targeting gp120 or gp41 | |
| Jin et al. | Antiviral functions of monoclonal antibodies against chikungunya virus | |
| Stefic et al. | Impact of HIV-1 diversity on its sensitivity to neutralization | |
| Sattentau | Envelope glycoprotein trimers as HIV-1 vaccine immunogens | |
| Ringel et al. | The hard way towards an antibody-based HIV-1 Env vaccine: lessons from other viruses | |
| Tolbert et al. | Structural basis for epitopes in the gp120 cluster A region that invokes potent effector cell activity | |
| Lambert et al. | HIV-1 envelope glycosylation and the signal peptide | |
| Schiavone et al. | Design and characterization of a peptide mimotope of the HIV-1 gp120 bridging sheet | |
| Bresk et al. | Induction of tier 1 HIV neutralizing antibodies by envelope trimers incorporated into a replication competent vesicular stomatitis virus vector | |
| Parker Miller et al. | A structural update of neutralizing epitopes on the HIV envelope, a moving target | |
| Mokhtary et al. | Recent progress in the discovery and development of monoclonal antibodies against viral infections | |
| Tannig et al. | Modulation of vaccine-induced HIV-1-specific immune responses by co-electroporation of PD-L1 encoding DNA | |
| Duerr et al. | V2-specific antibodies in HIV-1 vaccine research and natural infection: controllers or surrogate markers | |
| Anand et al. | Understudied factors influencing Fc-Mediated immune responses against viral infections | |
| Bruxelle et al. | HIV-1 entry and prospects for protecting against infection | |
| Burke et al. | Broadly neutralizing bovine antibodies: highly effective new tools against evasive pathogens? |